Analyst/Investor Meet - Earnings Call - Q1 - Audio Recording

Conference Call with Caplin Point Labs Management and Analysts on Q1FY23 Performance and Outlook. Listen to the full earnings transcript.

Caplin Point Laboratories Ltd has informed BSE that the Board of Directors of the Company at its meeting held on August 05, 2022, inter alia, has recommended a Final Dividend of Rs. 2 (100%) per equity share of Rs. 2 each for the financial year ended March 31, 2022. This shall be subject to approval of the shareholders at the forthcoming Annual General Meeting.

Outcome of Board Meeting

This is in response to the BSE e - mail communication having Ref. L/SURV/ONL/PV/RS/ 2022- 2023 / 138 dated August 2, 2022. In compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI (LODR) Regulations, 2015), the Company has promptly intimated to the Stock Exchanges of all events and information that may have a probable bearing on the operation / performance of the Company including all price sensitive information, as and when required from time to time. The Company do not have any undisclosed / potentially price sensitive information / event / announcement to be shared with the Stock Exchanges under Regulation 30 of SEBl (LODR) Regulations, 2015. Kindly take the same on record.

In terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby intimate that a conference call with the analysts/ fund houses post results will be held on Friday, August 5, 2022 at 17.00 hrs. (1ST) to discuss the financial performance of the Company for the quarter ended June 30, 2022.

The Exchange has sought clarification from Caplin Point Laboratories Ltd on August 02, 2022, with reference to Movement in Volume.The reply is awaited.

Intimation pursuant to Regulation 39(3) of SEBI (LODR) Regulations, 2015

Intimation pursuant to Regulation 39(3) of SEBI (LODR) Regulations, 2015